ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.72
0.56%
US Tech 100
17,658.00
0.32%
S&P 500
5,214.08
0.51%
US Dollar vs CAD
1.36881
0.07%
Bitcoin
62,993.68
-0.09%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) News

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARQT
DateTimeSourceHeadlineSymbolCompany
05/03/20243:00PMGlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
04/29/20243:00PMGlobeNewswire Inc.Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:ARQTArcutis Biotherapeutics Inc
04/10/20247:00AMGlobeNewswire Inc.Arcutis Appoints David Topper as Chief Financial OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
04/05/20243:00PMGlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
04/01/20246:00AMGlobeNewswire Inc.Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamNASDAQ:ARQTArcutis Biotherapeutics Inc
03/28/20247:00AMGlobeNewswire Inc.Arcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
03/11/20247:00AMGlobeNewswire Inc.Arcutis Promotes Todd Tucker to Chief Human Resources OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
03/10/20243:00PMGlobeNewswire Inc.Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
03/09/20243:00PMGlobeNewswire Inc.New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier DysfunctionNASDAQ:ARQTArcutis Biotherapeutics Inc
03/06/20244:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/06/20244:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/06/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/05/20243:00PMGlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20244:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20244:42PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20244:40PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20243:00PMGlobeNewswire Inc.Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20247:00AMGlobeNewswire Inc.Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
03/01/20243:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/01/20243:06PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARQTArcutis Biotherapeutics Inc
02/29/20244:00PMGlobeNewswire Inc.Arcutis to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
02/28/202410:30PMGlobeNewswire Inc.Arcutis Announces Pricing of $150 Million Public OfferingNASDAQ:ARQTArcutis Biotherapeutics Inc
02/28/20243:54PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
02/28/20243:21PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARQTArcutis Biotherapeutics Inc
02/28/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
02/28/20243:10PMGlobeNewswire Inc.Arcutis Announces Proposed Public OfferingNASDAQ:ARQTArcutis Biotherapeutics Inc
02/28/20243:00PMGlobeNewswire Inc.Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in JapanNASDAQ:ARQTArcutis Biotherapeutics Inc
02/27/20243:34PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARQTArcutis Biotherapeutics Inc
02/27/20246:48AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARQTArcutis Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ARQT

Your Recent History

USOTC
EMGE
Emergent Health (PK)
USOTC
TXTM
ProText Mobility (PK)
USOTC
SONG
Music Licensing (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
RDAR
Raadr (PK)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
CLNV
Clean Vision (QB)
USOTC
YCRM
Yuenglings Ice Cream (PK)
USOTC
IPIX
Innovation Pharmaceuticals (CE)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
GSTC
Globestar Therapeutics (PK)
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved